Cystic Fibrosis Market Size, Share, Trends, & Industry Analysis Report By Therapy Class, By Route of Administration, By Distribution Channel, and By Region – Market Forecast, 2026-2034
Description
The cystic fibrosis market size was valued at USD 13.70 billion in 2025 and is expected to reach USD 97.52 billion by 2034, growing at a CAGR of 24.4%. Cystic fibrosis is a chronic genetic disorder that predominantly affects the lungs and pancreas. The treatment approach also remains chronic, as it has to be continued every day. The new treatment strategies work towards maximizing lung function, symptom management, as well as identifying the root cause of CFTR.
What’s Included in Cystic Fibrosis Report?
The study offers a detailed analysis of the cystic fibrosis therapeutic market, encompassing CFTR modulators, mucolytic agents, pancreatic enzyme supplements, bronchodilator agents, and anti-infective agents. The analysis encompasses the use of treatments in pediatric and adult patient bases and encompasses the analysis of oral, inhaled, and injectable dosage forms. This study also encompasses the analysis of the competitive environment and regional scenarios surrounding the cystic fibrosis market.
What are Driving Factors and Emerging Trends of Cystic Fibrosis Market?
Based on our analysis, the cystic fibrosis market is experiencing steady growth across major healthcare systems worldwide. The key factors supporting this market include:
Expansion of CFTR Modulator Eligibility: Wider regulatory approvals based on several types of mutations are leading to an increased number of patients being treated and an enhanced demand for long-term therapy.
Early Diagnosis and Improved Life Expectancy: Effective newborn screening programs and better management of the disease provide opportunities to start treatment earlier and improve the lifespan of patients, leading to cumulative use of drugs.
Supportive Orphan Drug Incentives: Factors such as market exclusivity and accelerated approval remain incentives for investment in advanced treatments for cystic fibrosis.
These forces were evaluated together with trends regarding access, reimbursement, and compliance by analysts to ensure the provision of accurate forecasts.
Request a free sample copy or read the full market insights: cystic fibrosis market Report
Which Key Segments are Driving Cystic Fibrosis Market?
By Therapy Class Analysis
The CFTR modulators had the largest market share because of the disease-modifying effect and the long-term use in eligible populations.
By Route of Administration Analysis
The oral segment dominated the market due to higher patient adherence and convenience for chronic therapy management.
By Distribution Channel Analysis
Hospital pharmacies led the market due to their role in initiating therapy, managing reimbursement, and handling high cost orphan drugs.
Which is Dominating Region in Cystic Fibrosis Market?
North America: North America led as it had well-established reimbursement systems and had been one of the first to adopt CFTR modulators.
Asia Pacific: The Asia Pacific is anticipated to expand at the highest rate because of the growing diagnosis rate and the development of the healthcare infrastructure.
Where is Cystic Fibrosis Market Headed?
As per analysts, the cystic fibrosis market is headed for steady and sustained growth with the evolving treatment landscape of cystic fibrosis expanding towards CFTR eligibility and mutational agnostic strategies. Focus on diagnosis, prolonged survival, and access to specialized care is also contributing towards meeting the demand for innovative cystic fibrosis treatments.
What Cystic Fibrosis Market Report Reveals?
What is the global market size, growth trend, and CAGR for cystic fibrosis through 2034?
What are the factors driving the market growth?
Who are the top companies, and what is their relative position in terms of competitive positioning?
How do different therapy classes, including CFTR modulators and bronchodilators, shape the cystic fibrosis market landscape?
How does the market vary by route of administration, distribution channel, and geography, and which are the leading sectors?
What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
Where do new opportunities arise in the cystic fibrosis market?
Who are Major Cystic Fibrosis Market Contributors?
According to our study, a few firms are leading in the global market. The following are some of the major market contributors:
AbbVie Inc.
AstraZeneca
Bayer AG
Chiesi Farmaceutici S.p.A.
F. Hoffmann-La Roche AG
Genentech, Inc.
Gilead Sciences, Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Viatris Inc.
Market Segments Covered
By Therapy Class Outlook (Revenue, USD Billion, 2021-2034)
CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators
By Route of Administration Outlook (Revenue, USD Billion, 2021-2034)
Oral
Inhaled
Injectable
By Distribution Channel Outlook (Revenue, USD Billion, 2021-2034)
Hospital pharmacies
Retail pharmacies
Online & specialty pharmacies
By Regional Outlook (Revenue, USD Billion, 2021-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherland
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Saudi Arabia
UAE
South Africa
Israel
Rest of Middle East & Africa
What’s Included in Cystic Fibrosis Report?
The study offers a detailed analysis of the cystic fibrosis therapeutic market, encompassing CFTR modulators, mucolytic agents, pancreatic enzyme supplements, bronchodilator agents, and anti-infective agents. The analysis encompasses the use of treatments in pediatric and adult patient bases and encompasses the analysis of oral, inhaled, and injectable dosage forms. This study also encompasses the analysis of the competitive environment and regional scenarios surrounding the cystic fibrosis market.
What are Driving Factors and Emerging Trends of Cystic Fibrosis Market?
Based on our analysis, the cystic fibrosis market is experiencing steady growth across major healthcare systems worldwide. The key factors supporting this market include:
Expansion of CFTR Modulator Eligibility: Wider regulatory approvals based on several types of mutations are leading to an increased number of patients being treated and an enhanced demand for long-term therapy.
Early Diagnosis and Improved Life Expectancy: Effective newborn screening programs and better management of the disease provide opportunities to start treatment earlier and improve the lifespan of patients, leading to cumulative use of drugs.
Supportive Orphan Drug Incentives: Factors such as market exclusivity and accelerated approval remain incentives for investment in advanced treatments for cystic fibrosis.
These forces were evaluated together with trends regarding access, reimbursement, and compliance by analysts to ensure the provision of accurate forecasts.
Request a free sample copy or read the full market insights: cystic fibrosis market Report
Which Key Segments are Driving Cystic Fibrosis Market?
By Therapy Class Analysis
The CFTR modulators had the largest market share because of the disease-modifying effect and the long-term use in eligible populations.
By Route of Administration Analysis
The oral segment dominated the market due to higher patient adherence and convenience for chronic therapy management.
By Distribution Channel Analysis
Hospital pharmacies led the market due to their role in initiating therapy, managing reimbursement, and handling high cost orphan drugs.
Which is Dominating Region in Cystic Fibrosis Market?
North America: North America led as it had well-established reimbursement systems and had been one of the first to adopt CFTR modulators.
Asia Pacific: The Asia Pacific is anticipated to expand at the highest rate because of the growing diagnosis rate and the development of the healthcare infrastructure.
Where is Cystic Fibrosis Market Headed?
As per analysts, the cystic fibrosis market is headed for steady and sustained growth with the evolving treatment landscape of cystic fibrosis expanding towards CFTR eligibility and mutational agnostic strategies. Focus on diagnosis, prolonged survival, and access to specialized care is also contributing towards meeting the demand for innovative cystic fibrosis treatments.
What Cystic Fibrosis Market Report Reveals?
What is the global market size, growth trend, and CAGR for cystic fibrosis through 2034?
What are the factors driving the market growth?
Who are the top companies, and what is their relative position in terms of competitive positioning?
How do different therapy classes, including CFTR modulators and bronchodilators, shape the cystic fibrosis market landscape?
How does the market vary by route of administration, distribution channel, and geography, and which are the leading sectors?
What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
Where do new opportunities arise in the cystic fibrosis market?
Who are Major Cystic Fibrosis Market Contributors?
According to our study, a few firms are leading in the global market. The following are some of the major market contributors:
AbbVie Inc.
AstraZeneca
Bayer AG
Chiesi Farmaceutici S.p.A.
F. Hoffmann-La Roche AG
Genentech, Inc.
Gilead Sciences, Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Viatris Inc.
Market Segments Covered
By Therapy Class Outlook (Revenue, USD Billion, 2021-2034)
CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators
By Route of Administration Outlook (Revenue, USD Billion, 2021-2034)
Oral
Inhaled
Injectable
By Distribution Channel Outlook (Revenue, USD Billion, 2021-2034)
Hospital pharmacies
Retail pharmacies
Online & specialty pharmacies
By Regional Outlook (Revenue, USD Billion, 2021-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherland
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Saudi Arabia
UAE
South Africa
Israel
Rest of Middle East & Africa
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Cystic Fibrosis Market Insights
- 4.1. Cystic Fibrosis Market – Market Snapshot
- 4.2. Cystic Fibrosis Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Expansion of CFTR Modulator Eligibility
- 4.2.1.2. Supportive Orphan Drug Incentives
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Therapy Cost and Uneven Access
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Cystic Fibrosis Market Trends
- 4.6. Value Chain Analysis
- 5. Global Cystic Fibrosis Market, by Therapy Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 5.3. CFTR Modulators
- 5.3.1. Global Cystic Fibrosis Market, by CFTR Modulators, by Region, 2021-2034 (USD Billion)
- 5.4. Pancreatic Enzyme Supplements
- 5.4.1. Global Cystic Fibrosis Market, by Pancreatic Enzyme Supplements, by Region, 2021-2034 (USD Billion)
- 5.5. Mucolytics
- 5.5.1. Global Cystic Fibrosis Market, by Mucolytics, by Region, 2021-2034 (USD Billion)
- 5.6. Bronchodilators
- 5.6.1. Global Cystic Fibrosis Market, by Bronchodilators, by Region, 2021-2034 (USD Billion)
- 6. Global Cystic Fibrosis Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 6.3. Oral
- 6.3.1. Global Cystic Fibrosis Market, by Oral, by Region, 2021-2034 (USD Billion)
- 6.4. Inhaled
- 6.4.1. Global Cystic Fibrosis Market, by Inhaled, by Region, 2021-2034 (USD Billion)
- 6.5. Injectable
- 6.5.1. Global Cystic Fibrosis Market, by Injectable, by Region, 2021-2034 (USD Billion)
- 7. Global Cystic Fibrosis Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 7.3. Hospital pharmacies
- 7.3.1. Global Cystic Fibrosis Market, by Hospital pharmacies, by Region, 2021-2034 (USD Billion)
- 7.4. Retail pharmacies
- 7.4.1. Global Cystic Fibrosis Market, by Retail pharmacies, by Region, 2021-2034 (USD Billion)
- 7.5. Online & specialty pharmacies
- 7.5.1. Global Cystic Fibrosis Market, by Online & specialty pharmacies, by Region, 2021-2034 (USD Billion)
- 8. Global Cystic Fibrosis Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Cystic Fibrosis Market Assessment, By Geography, 2021-2034 (USD Billion)
- 8.3. Cystic Fibrosis Market – North America
- 8.3.1. North America: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.3.2. North America: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.3.3. North America: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.3.4. Cystic Fibrosis Market – U.S.
- 8.3.4.1. U.S.: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.3.4.2. U.S.: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.3.4.3. U.S.: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.3.5. Cystic Fibrosis Market – Canada
- 8.3.5.1. Canada: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.3.5.2. Canada: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.3.5.3. Canada: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4. Cystic Fibrosis Market – Europe
- 8.4.1. Europe: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.2. Europe: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.3. Europe: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.4. Cystic Fibrosis Market – UK
- 8.4.4.1. UK: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.4.2. UK: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.4.3. UK: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.5. Cystic Fibrosis Market – France
- 8.4.5.1. France: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.5.2. France: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.5.3. France: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.6. Cystic Fibrosis Market – Germany
- 8.4.6.1. Germany: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.6.2. Germany: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.6.3. Germany: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.7. Cystic Fibrosis Market – Italy
- 8.4.7.1. Italy: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.7.2. Italy: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.7.3. Italy: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.8. Cystic Fibrosis Market – Spain
- 8.4.8.1. Spain: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.8.2. Spain: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.8.3. Spain: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.9. Cystic Fibrosis Market – Netherlands
- 8.4.9.1. Netherlands: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.9.2. Netherlands: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.9.3. Netherlands: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.10. Cystic Fibrosis Market – Russia
- 8.4.10.1. Russia: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.10.2. Russia: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.10.3. Russia: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.4.11. Cystic Fibrosis Market – Rest of Europe
- 8.4.11.1. Rest of Europe: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5. Cystic Fibrosis Market – Asia Pacific
- 8.5.1. Asia Pacific: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.2. Asia Pacific: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.3. Asia Pacific: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.4. Cystic Fibrosis Market – China
- 8.5.4.1. China: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.4.2. China: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.4.3. China: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.5. Cystic Fibrosis Market – India
- 8.5.5.1. India: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.5.2. India: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.5.3. India: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.6. Cystic Fibrosis Market – Malaysia
- 8.5.6.1. Malaysia: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.6.2. Malaysia: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.6.3. Malaysia: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.7. Cystic Fibrosis Market – Japan
- 8.5.7.1. Japan: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.7.2. Japan: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.7.3. Japan: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.8. Cystic Fibrosis Market – Indonesia
- 8.5.8.1. Indonesia: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.8.2. Indonesia: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.8.3. Indonesia: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.9. Cystic Fibrosis Market – South Korea
- 8.5.9.1. South Korea: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.9.2. South Korea: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.9.3. South Korea: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.10. Cystic Fibrosis Market – Australia
- 8.5.10.1. Australia: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.10.2. Australia: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.10.3. Australia: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.5.11. Cystic Fibrosis Market – Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6. Cystic Fibrosis Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6.4. Cystic Fibrosis Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6.5. Cystic Fibrosis Market – UAE
- 8.6.5.1. UAE: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.5.2. UAE: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.5.3. UAE: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6.6. Cystic Fibrosis Market – Israel
- 8.6.6.1. Israel: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.6.2. Israel: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.6.3. Israel: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6.7. Cystic Fibrosis Market – South Africa
- 8.6.7.1. South Africa: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.7.2. South Africa: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.7.3. South Africa: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.6.8. Cystic Fibrosis Market – Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.7. Cystic Fibrosis Market – Latin America
- 8.7.1. Latin America: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.7.2. Latin America: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.7.3. Latin America: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.7.4. Cystic Fibrosis Market – Mexico
- 8.7.4.1. Mexico: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.7.4.2. Mexico: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.7.4.3. Mexico: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.7.5. Cystic Fibrosis Market – Brazil
- 8.7.5.1. Brazil: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.7.5.2. Brazil: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.7.5.3. Brazil: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.7.6. Cystic Fibrosis Market – Argentina
- 8.7.6.1. Argentina: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.7.6.2. Argentina: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.7.6.3. Argentina: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 8.7.7. Cystic Fibrosis Market – Rest of Latin America
- 8.7.7.1. Rest of Latin America: Cystic Fibrosis Market, by Therapy Class, 2021-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Cystic Fibrosis Market, by Route of Administration, 2021-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Cystic Fibrosis Market, by Distribution Channel, 2021-2034 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. AbbVie Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. AstraZeneca
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bayer AG
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Chiesi Farmaceutici S.p.A.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. F. Hoffmann-La Roche AG
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Genentech, Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Gilead Sciences, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Mylan N.V.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Novartis AG
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Teva Pharmaceutical Industries Ltd.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Vertex Pharmaceuticals Inc.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Viatris Inc.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
